Clincal Studies (Boberg Group)
Kirsten Muri Boberg
The main aim of the clinical studies in primary sclerosing cholangitis (PSC) is to determine effective means of treatment and diagnosis. Challenges are manifold, but the lack of diagnostic markers for PSC and for cholangiocarcinoma in PSC means that both conditions are diagnosed late. The lack of effective medical treatment of PSC means that, unfortunately, PSC is the leading indication for liver transplantation in Norway.
PSC is a slowly progressive disease with a course of one to two decades from the identification of early stages of disease manifestations until end-stage liver disease. This results in difficulties in establishing a robust level of evidence for the benefit of any treatment in delaying liver transplantation. At present, no medical therapy with proven efficacy is available. Several compounds are being investigated in phase I and phase II trials. So far the Norwegian PSC research center participates in the nor-ursodeoxycholic acid trial from the Falk Pharmaceutical company, but other drugs will also be tested. Ongoing studies also aim to determine the optimal mode of endoscopic therapy for narrow strictures (dilatation or stenting).
Establishing diagnostic markers for PSC in patients with inflammatory bowel disease could serve crucial for diagnosing patients before the scarring of the bile ducts has become irreversible. In collaboration with the Inflammatory Bowel Disease in South Eastern Norway (IBSEN) study group, ongoing efforts aim to determine factors that correlate with even sub-clinical bile duct changes on cholangiography in patients with inflammatory bowel disease. Likewise, it is a priority topic to determine biomarkers for pre-clinical cholangiocarcinoma in patients with PSC to allow for effective treatments (see LINK TIL FUNCTIONAL GENOMICS).
All studies within the clinical research groups are performed in close collaboration with the International PSC study group (www.ipscsg.org). Key investigators are clinicians, typically funded by Oslo University Hospital and Haukeland University Hospital. Some dedicated time for research is supported by the Norwegian PSC Research Center.
Photo Øystein H. Horgmo, University of Oslo
From front and to the left: Kristine Wiencke, Kirsten Muri Boberg, Trine Folseraas, Kristian Bjøro, Erik Schrumpf and Liv Wenche Thorbjørnsen
Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology
Mar 15, 2017
Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research
Mar 7, 2017
Mar 6, 2017
Mar 2, 2017
Kirsten M. Boberg